Form 144 - Report of proposed sale of securities:
SEC Accession No. 0000947871-24-000688
Filing Date
2024-08-13
Accepted
2024-08-13 16:12:22
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 3214
  Complete submission text file 0000947871-24-000688.txt   4830
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Reporting) CIK: 0001055951 (see all company filings)

EIN.: 133976876 | State of Incorp.: DE
Type: 144

Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Subject) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 001-39264 | Film No.: 241201581
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)